Valuation: Celestra Inc.

Market Cap 13.41B 9.67M 8.29M 7.75M 7.1M 13.32M 926M 13.5M 91.6M 35.72M 465M 36.32M 35.53M 1.54B P/E 2024
-0.4x
P/E 2025 -1.14x
Enterprise Value 17.19B 12.4M 10.63M 9.94M 9.1M 17.08M 1.19B 17.31M 117M 45.81M 596M 46.58M 45.56M 1.97B EV / Sales 2024
5.8x
EV / Sales 2025 8.56x
Free-Float
78.31%
Yield 2024 *
-
Yield 2025 -
3 years 4,245
Extreme 4244.999997
48,000
5 years 4,245
Extreme 4244.999997
143,000
10 years 4,245
Extreme 4244.999997
261,500
Manager TitleAgeSince
Chief Executive Officer 30 2024-03-28
Comptroller/Controller/Auditor 47 2025-03-30
Director TitleAgeSince
Director/Board Member 30 2024-03-28
Director/Board Member 42 2025-09-24
Director/Board Member 41 2024-06-13
Date Insider Type Main position Quantity % Market Cap.
6/17/24 Sell

Chief Executive Officer

100,000 -
Change 5-day change 1-year change 3-year change Capi.($)
-20.63%-.--%-.--%-86.19% 9.67M
+1.09%+5.26%+4.52%+26.24% 51.61B
-1.07%+2.82%+465.96%+586.75% 44.89B
+1.47%+9.79%+35.92%+21.40% 42.77B
+1.44%+7.77%+19.38%+92.75% 42.58B
-0.93%-4.33%+16.18%+53.76% 31.82B
+1.32%+7.30%+33.89%+150.10% 17.33B
-0.60%+1.93% - - 16.63B
+0.03%+3.41%+6.55%+32.10% 14.76B
+1.28%+5.41%+82.40%+47.43% 14.09B
Average -1.66%+0.61%+73.87%+102.70% 27.65B
Weighted average by Cap. +0.48%+4.72%+99.57%+146.29%

Financials

2024 2025
Net sales 8.5B 6.13M 5.25M 4.92M 4.5M 8.45M 587M 8.56M 58.09M 22.65M 295M 23.03M 22.53M 975M 2.01B 1.45M 1.24M 1.16M 1.06M 1.99M 139M 2.02M 13.72M 5.35M 69.63M 5.44M 5.32M 230M
Net income -46.92B -33.86M -29M -27.14M -24.84M -46.62M -3.24B -47.24M -321M -125M -1.63B -127M -124M -5.38B -11.77B -8.49M -7.28M -6.81M -6.23M -11.69M -813M -11.85M -80.43M -31.37M -408M -31.89M -31.2M -1.35B
Net Debt 29.34B 21.17M 18.13M 16.97M 15.53M 29.15M 2.03B 29.53M 200M 78.17M 1.02B 79.49M 77.76M 3.37B 3.79B 2.73M 2.34M 2.19M 2M 3.76M 261M 3.81M 25.86M 10.09M 131M 10.26M 10.03M 434M
Logo Celestra Inc.
Celestra Inc, formerly Clinomics Inc, is a Korea-based company principally operates precision medical business based on genome-based healthcare and liquid biopsy platforms. The Company provides genome-based healthcare products and services that predict physical characteristics and diseases based on genome diagnosis and examination. The Company is engaged in the sale of medical devices and cancer diagnosis and monitoring that extract blood cells and deoxyribo nucleic acid (DNA) to diagnose patients. The Company is developing multi-omics-based early diagnosis service technology for diseases such as cancer.
Employees
48
  1. Stock Market
  2. Stocks
  3. A352770 Stock